Event Brief
Biogen to advance tau-targeting Alzheimer drug to Phase 3
Filed: May 14, 2026 at 1:03 PM ET
Summary: Biogen said it will move its tau-targeting Alzheimer’s drug into Phase 3 despite disappointing mid-stage results.
WHO: Biogen
WHAT: Biogen said it will advance an experimental tau-targeting Alzheimer’s drug to Phase 3 testing despite disappointing mid-stage trial data.
WHEN: May 14, 2026 at 12:10 PM ET
WHERE: Location not specified
WHY: Signals suggested the treatment decreases tau levels and slows cognitive decline, particularly at the lowest dose.
ℹ️ This event is analyzed using pattern arcs, velocity indicators, and source analysis in our MI Console.
Know more. Read less.
The BriefBrief follows the story, so you don't have to read every article. See what happened, how it changed, and where it came from, all in one place.
Same format. Every time.
See how stories unfold →